These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15132770)

  • 1. Targeted gene delivery using humanized single-chain antibody with negatively charged oligopeptide tail.
    Suzuki M; Takayanagi A; Shimizu N
    Cancer Sci; 2004 May; 95(5):424-9. PubMed ID: 15132770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant single-chain antibodies with various oligopeptide tails for targeted gene delivery.
    Suzuki M; Takayanagi A; Shimizu N
    Gene Ther; 2003 May; 10(9):781-8. PubMed ID: 12704417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies: improved immunogene approach.
    Chen J; Gamou S; Takayanagi A; Ohtake Y; Ohtsubo M; Shimizu N
    Cancer Gene Ther; 1998; 5(6):357-64. PubMed ID: 9917090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Targeting delivery of therapeutic genes using monoclonal antibody; immunogene approach].
    Takayanagi A; Chen J; Gamou S; Shimizu N
    Nihon Rinsho; 1998 Mar; 56(3):731-6. PubMed ID: 9549365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogene approach toward cancer therapy using erythrocyte growth factor receptor-mediated gene delivery.
    Shimizu N; Chen J; Gamou S; Takayanagi A
    Cancer Gene Ther; 1996; 3(2):113-20. PubMed ID: 8729910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor-specific Fab immunogene.
    Ohtake Y; Chen J; Gamou S; Takayanagi A; Mashima Y; Oguchi Y; Shimizu N
    Jpn J Cancer Res; 1999 Apr; 90(4):460-8. PubMed ID: 10363586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted in vivo delivery of therapeutic gene into experimental squamous cell carcinomas using anti-epidermal growth factor receptor antibody: immunogene approach.
    Chen J; Gamou S; Takayanagi A; Ohtake Y; Ohtsubo M; Shimizu N
    Hum Gene Ther; 1998 Dec; 9(18):2673-81. PubMed ID: 9874265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
    Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
    Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
    Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
    Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.
    van Beusechem VW; Grill J; Mastenbroek DC; Wickham TJ; Roelvink PW; Haisma HJ; Lamfers ML; Dirven CM; Pinedo HM; Gerritsen WR
    J Virol; 2002 Mar; 76(6):2753-62. PubMed ID: 11861842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid.
    Volpers C; Thirion C; Biermann V; Hussmann S; Kewes H; Dunant P; von der Mark H; Herrmann A; Kochanek S; Lochmüller H
    J Virol; 2003 Feb; 77(3):2093-104. PubMed ID: 12525644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.
    Bier H; Hoffmann T; Haas I; van Lierop A
    Cancer Immunol Immunother; 1998 May; 46(3):167-73. PubMed ID: 9625540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin.
    Schmidt M; Reiser P; Hills D; Gullick WJ; Wels W
    Int J Cancer; 1998 Mar; 75(6):878-84. PubMed ID: 9506533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma.
    Blackwell JL; Miller CR; Douglas JT; Li H; Reynolds PN; Carroll WR; Peters GE; Strong TV; Curiel DT
    Arch Otolaryngol Head Neck Surg; 1999 Aug; 125(8):856-63. PubMed ID: 10448731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
    Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
    MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
    Xu L; Huang CC; Huang W; Tang WH; Rait A; Yin YZ; Cruz I; Xiang LM; Pirollo KF; Chang EH
    Mol Cancer Ther; 2002 Mar; 1(5):337-46. PubMed ID: 12489850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor.
    Ozawa S; Ueda M; Ando N; Abe O; Minoshima S; Shimizu N
    Int J Cancer; 1989 Jan; 43(1):152-7. PubMed ID: 2783415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor.
    Nakayashiki N; Yoshikawa K; Nakamura K; Hanai N; Okamoto K; Okamoto S; Mizuno M; Wakabayashi T; Saga S; Yoshida J; Takahashi T
    Jpn J Cancer Res; 2000 Oct; 91(10):1035-43. PubMed ID: 11050475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector.
    Huang H; Yu H; Tang G; Wang Q; Li J
    Biomaterials; 2010 Mar; 31(7):1830-8. PubMed ID: 19942284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
    Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
    Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.